“…Following the discovery of the role of cholesterol in cardiovascular disease (CVD) in 1856 (2), many studies confirmed the relationship between high blood cholesterol levels and an increased probability of CVD (3,4). Consequently, cholesterol reduction was identified as one of the main strategies for the treatment and control of CVD (5,6). The enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase was identified as a rate-limiting enzyme in the biosynthesis of cholesterol (7).…”